EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database

Natsuko Tokushige iD, Yasuhiro Hayashi, Junichi Omura, Tatsunori Jinnai, Tatsuya Atsumi

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Natsuko Tokushige und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan. Hauptthemen laut MEDLINE: Connective Tissue Diseases, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the diagnostic and therapeutic landscape for patients with connective tissue disease (CTD) and CTD-associated pulmonary arterial hypertension (CTD-PAH) in acute-care general hospitals in Japan.

Methods

We conducted a retrospective cohort study by analysing the Medical Data Vision (MDV) database from April 2008 to September 2020. CTD patients who prescribed immunosuppressants were included in cohort 1, and CTD-PAH patients extracted from cohort 1 were included in cohort 2. Patient characteristics, diagnostic screening frequencies for PAH, and initial PAH-specific treatment patterns were assessed.

Results

Overall, 16,648 patients with CTD and 81 patients with CTD-PAH were included in cohorts 1 and 2, respectively. The frequencies of screening tests for PAH, including brain natriuretic peptide (BNP), transthoracic echocardiogram (TTE), and ‘diffusing capacity’ of the ‘lungs for carbon monoxide’ (DLCO), among CTD patients were 0.7, 0.3, and 0.1 tests/person-year, respectively. The most common initial PAH-specific treatment therapy was monotherapy (87.7%), followed by dual therapy (7.4%) and triple therapy (2.5%).

Conclusion

This is the first study to describe the patient flow from PAH diagnosis to initial PAH-specific treatment for real-world patients who were followed regularly due to CTD in Japanese clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Connective Tissue DiseasesPulmonary Arterial HypertensionHumansMaleFemaleMiddle AgedJapanRetrospective StudiesAgedAdultDatabases, FactualHypertension, PulmonaryImmunosuppressive AgentsEast Asian People

Stichwörter der Autor:innen

Connective tissue diseaseDPCpulmonary arterial hypertensionscreening testsystemic sclerosis

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

ORCID-Profile: Natsuko Tokushige

Zitieren

APA

Tokushige, N., Hayashi, Y., Omura, J., Jinnai, T., & Atsumi, T. (2024). Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roae033

Vancouver

Tokushige N, Hayashi Y, Omura J, Jinnai T, Atsumi T. Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database. Modern Rheumatology. 2024. doi:10.1093/mr/roae033

BibTeX
@article{Tokushige2024,
  author = {Tokushige, Natsuko and Hayashi, Yasuhiro and Omura, Junichi and Jinnai, Tatsunori and Atsumi, Tatsuya},
  title = {Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae033}
}
Kostenlos starten →